← All trials
NCT01551394
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2012
- Primary completion
- Dec 1, 2014
- Completion date
- Dec 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 272
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- PENTA FoundationLead sponsor
- University of TartuOverall official - principal investigator
- University of PadovaOverall official - principal investigator
- Institut National de la Santé Et de la Recherche Médicale, FranceStudy chair
- ChiesiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.